Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. The product is developed and produced by Dutch biotechnology company Micreos.
The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.
References
Staphefekt Wikipedia(Text) CC BY-SA